Mechanism of action of the oxazolidinone antibacterial agents

Bibliography

• BRADLEY SF: Methicillin-resistant Staphylococcusaureus: long-term concerns. Am. J. Med. (1999) 106:2–10.
   Google Scholar
• JACOBS MR: Drug-resistant Streptococcus pneumo-niae: rational antibiotic choices. Am. J. Med. (1999) 106:19–25.
   Google Scholar
• SLEE AM, WUONOLA MA, MCRIPLEY RJ et al: Oxazolidi-nones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP105 and DuP721. Antimicrob. Agents Chemother. (1987) 31:1791–1797.
   PubMed Web of Science ®Google Scholar
• ••Elongation using polysomes is not inhibited. Therefore,oxazolidinones are not classic peptidyl transferase inhibitors.
   Google Scholar
• BATTS DH, STALKER DJ, PEEL BG etal.: U-100592 Phase I, multiple-oral dose randomized, placebo-controlled, safety, tolerance and pharmacokinetics in healthy volunteers for 14.25 days using bulk drug in capsules. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1995). Abstract F226.
   Google Scholar
• PAWSEY SD, DALEY-YATES PT, WAJSZCZUK CP, STALKER DJ: U-100766 safety, toleration and pharmacokinetics after oral and intravenous (IV) administration. 1st European Congress of Chemotherapy Glasgow, UK (1996). Abstract F151.
   Google Scholar
• Oxazolidinones: a new class of antibiotics. 2nd European Congress of Chemotherapy and 7th Biennial Conference on Antilnfective Agents and Chemotherapy (Final Program). (1998)93.
   Google Scholar
• •First (short) description of Phase II results for the oxazolidi-none, linezolid (Pharmacia & Upjohn).
   Google Scholar
• BATTS D: Linezolid clinical development program: End of Phase II results. 8th International Congress on Infectious Diseases. Boston, USA (1998) Abstract 40.006.
   Google Scholar
• BRICKNER SJ, HUTCHINSON DK, BARBACHYN MR et al.: Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. (1996) 39:673–679.
   PubMed Web of Science ®Google Scholar
• •First description of synthesis and antibacterial activity of eperezolid (U-100592) and linezolid (U–100766).
   Google Scholar
• ELIOPOLUS GM, WENNERSTEN CB, GOLD HS, MOELLERING RC, JR.: In vitro activities of new oxazolidinone antimicrobial agents against entero-cocci. Antimicrob. Agents Chemother. (1996) 40:1745–1747.
   Google Scholar
• JONES RN, JOHNSON DM, ERWIN ME: In vitro antimicro-bial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. Agents Chemother. (1996) 40:720–726.
   PubMed Web of Science ®Google Scholar
• KAATZ GW, SEO SM: In vitro activities of oxazolidinone compounds U-100592 and U-100766 against t Staphylococcus aureus and Staphylococcus epider-midis. Antimicrob. Agents Chemother. (1996) 40:799–801.
   PubMed Web of Science ®Google Scholar
• MASON EO, LAMBERTH LB, KAPLAN SL : In vitro activi-ties of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1996) 40:1039–1040.
   PubMed Web of Science ®Google Scholar
• ZURENKO GE, YAGI BH, SCHAADT RD et al.: In vitro activities of U-100592 and U-100766, novel oxazolidi-none antibacterial agents. Antimicrob. Agents Chemother. (1996) 40:839–845.
   PubMed Web of Science ®Google Scholar
• JORGENSEN JH, MCELMEEL ML, TRIPPY CW: In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimi-crob. Agents Chemother. (1997) 41:465–467.
   PubMed Web of Science ®Google Scholar
• ZURENKO GE, FORD CW, HUTCHINSON DK, BRICKNER SJ, BARBACHYN MR: Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid. Exp. Opin. Invest. Drugs (1997) 6:151–158.
   PubMedGoogle Scholar
• •Review of discovery and development of eperezolid and linezolid.
   Google Scholar
• EUSTICE DC, FELDMAN PA, SLEE AM: Mechanism of action of DuP 721, a new antibacterial agent: Effects on macromolecular synthesis. Biochem. Biophys. Res. Comm. (1988) 150:965–971.
   PubMed Web of Science ®Google Scholar
• SHINABARGER DL, MAROTTI KR, MURRAY RW et al.:Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. (1997) 41:2132–2136.
   PubMed Web of Science ®Google Scholar
• •First report of linezolid and eperezolid mechanism of action.
   Google Scholar
• BUYSSE JM, DEMYAN WF, DUNYAK DS, STAPERT D, HAMEL JC, FORD CW: Mutation of the AcrAB antibiotic efflux pump in Escherichia coli confers susceptibility to oxazolidinone antibiotics. 36th International Confer-ence on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996). Abstract C42.
   Google Scholar
• NIKAIDO H: Multidrug efflux pumps of Gram-negative bacteria. J Bacteriol. (1996) 178:5853–5859.
   PubMed Web of Science ®Google Scholar
• EUSTICE DC, FELDMAN PA, ZAJAC I, SLEE AM: Mechanism of action of DuP 721: Inhibition of an early event during initiation of protein synthesis. Antimi-crob. Agents Chemother. (1988) 32:1218–1222.
   PubMed Web of Science ®Google Scholar
• UN AH, MURRAY RW, SCHAADT RD et al.: The oxazolidi-none eperezolid binds to the 505 ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. (1977) 41:2127–2131.
   Google Scholar
• •First demonstration of oxazolidinone binding to ribosomes.
   Google Scholar
• FERNANDEZ-MUNOZ R, MONRO RE, TORRES-PINEDO R VAZQUEZ D: Substrate-and antibiotic-binding sites at the peptidyl-transferase center of Escherichia coli ribosomes. Studies on the chloramphenicol, lincomycin and erythromycin sites. Eur. J. Biochem. (1971) 23:185–193.
   PubMedGoogle Scholar
• BURGHARDT H, SCHIMZ KL, MULLER M: On the target of a novel class of antibiotics, oxazolidinones, active against multidrug-resistant Gram-positive bacteria. FEBS Lett. (1998) 425:40–44.
   PubMed Web of Science ®Google Scholar
• •Demonstration that initiator tRNA binding is affected by oxazolidinones.
   Google Scholar
• MATASSOVA NB, RODNINA MV, ENDERMANN R et al: Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA (1999) (In Press).
   Google Scholar
• •First demonstration of crosslinking of oxazolidinone to both subunits.
   Google Scholar
• MOAZED D, NOLLER HF: Interaction of tRNA with 23SrRNA in the ribosomal A, P, and E sites. Cell (1989) 57:585–597.
   PubMed Web of Science ®Google Scholar
• SWANEY SM, AOKI H, GANOZA MC, SHINABARGER DL:The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. (1998) 42:3251–3255.
   PubMed Web of Science ®Google Scholar
• •First report of a ribosome reaction inhibited by oxazolidinone.
   Google Scholar
• DALY JS, ELIOPOULOS GM, WILEY S, MOELLERING RC,JR.: Mechanism of action and in vitro and in vivo activi-ties of S-6123, a new oxazolidinone compound. Antimi-crob. Agents Chemother. (1988) 32 :1341–1346 .
   Google Scholar
• SWANEY SM, SHINABARGER DL, SCHAADT RD, BOCK JH, SLIGHTOM JL, ZURENKO GE: Oxazolidinone resistance is associated with a mutation in the peptidyl transfe-rase region of 23S rRNA. 38th ICAAC, San Diego, California, USA (1998) Abstract C–104.
   Google Scholar
• ••First identification of an oxazolidinone resistance mutation.
   Google Scholar
• MURRAY RW, SCHAADT RD, ZURENKO GE, MAROTTI KR: Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay. Antimicrob. Agents Chemother. (1998) 42:947–950.
   PubMed Web of Science ®Google Scholar
• HUMMEL H, BOCK A: 23S ribosomal RNA mutations in halobacteria conferring resistance to the anti-80S ribosome targeted antibiotic anisomycin. Nuc. Acids Res. (1987) 15:2431–2433.
   PubMed Web of Science ®Google Scholar
• WADA A, OHTA H, KULTHANAN K, HIRAMATSU K: Molecular cloning and mapping of 16S-23S rRNA gene complexes of Staphylococcus aureus. J. Bacteriol. (1993) 175:7483–7487.
   PubMed Web of Science ®Google Scholar
• NINIO J: Gene conversion as a focusing mechanism for correlated mutations. Mot. Gen. Genetics (1996) 251:503–508.
   Web of Science ®Google Scholar